Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.

Curtis M, Kenny HA, Ashcroft B, Mukherjee A, Johnson A, Zhang Y, Helou Y, Batlle R, Liu X, Gutierrez N, Gao X, Yamada SD, Lastra R, Montag A, Ahsan N, Locasale JW, Salomon AR, Nebreda AR, Lengyel E.

Cell Metab. 2018 Aug 28. pii: S1550-4131(18)30508-4. doi: 10.1016/j.cmet.2018.08.007. [Epub ahead of print]

PMID:
30174305
2.

Organotypic 3D Models of the Ovarian Cancer Tumor Microenvironment.

Watters KM, Bajwa P, Kenny HA.

Cancers (Basel). 2018 Aug 9;10(8). pii: E265. doi: 10.3390/cancers10080265. Review.

3.

Adipocyte-induced CD36 expression drives ovarian cancer progression and metastasis.

Ladanyi A, Mukherjee A, Kenny HA, Johnson A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag A, Yamada SD, Abumrad NA, Lengyel E.

Oncogene. 2018 Apr;37(17):2285-2301. doi: 10.1038/s41388-017-0093-z. Epub 2018 Feb 5.

4.

A High-Throughput Screening Model of the Tumor Microenvironment for Ovarian Cancer Cell Growth.

Lal-Nag M, McGee L, Guha R, Lengyel E, Kenny HA, Ferrer M.

SLAS Discov. 2017 Jun;22(5):494-506. doi: 10.1177/2472555216687082. Epub 2017 Jan 31.

5.

Unsaturated Fatty Acids Maintain Cancer Cell Stemness.

Mukherjee A, Kenny HA, Lengyel E.

Cell Stem Cell. 2017 Mar 2;20(3):291-292. doi: 10.1016/j.stem.2017.02.008.

6.

Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.

Zhang Y, Sriraman SK, Kenny HA, Luther E, Torchilin V, Lengyel E.

Mol Cancer Ther. 2016 Oct;15(10):2282-2293. Epub 2016 Jul 27.

7.

Modeling the Early Steps of Ovarian Cancer Dissemination in an Organotypic Culture of the Human Peritoneal Cavity.

Peters PN, Schryver EM, Lengyel E, Kenny H.

J Vis Exp. 2015 Dec 31;(106):e53541. doi: 10.3791/53541.

8.

Molecular pathways: trafficking of metabolic resources in the tumor microenvironment.

Romero IL, Mukherjee A, Kenny HA, Litchfield LM, Lengyel E.

Clin Cancer Res. 2015 Feb 15;21(4):680-6. doi: 10.1158/1078-0432.CCR-14-2198. Review.

9.

Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy.

Kenny HA, Lal-Nag M, White EA, Shen M, Chiang CY, Mitra AK, Zhang Y, Curtis M, Schryver EM, Bettis S, Jadhav A, Boxer MB, Li Z, Ferrer M, Lengyel E.

Nat Commun. 2015 Feb 5;6:6220. doi: 10.1038/ncomms7220. Erratum in: Nat Commun. 2016;7:10649.

10.

Three-dimensional modeling of ovarian cancer.

White EA, Kenny HA, Lengyel E.

Adv Drug Deliv Rev. 2014 Dec 15;79-80:184-92. doi: 10.1016/j.addr.2014.07.003. Epub 2014 Jul 14. Review.

11.

Urokinase plasminogen activator system-targeted delivery of nanobins as a novel ovarian cancer therapy.

Zhang Y, Kenny HA, Swindell EP, Mitra AK, Hankins PL, Ahn RW, Gwin K, Mazar AP, O'Halloran TV, Lengyel E.

Mol Cancer Ther. 2013 Dec;12(12):2628-39. doi: 10.1158/1535-7163.MCT-13-0204. Epub 2013 Sep 23.

12.

Epithelial ovarian cancer experimental models.

Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, Nephew KP, Hales DB, Stack MS.

Oncogene. 2014 Jul 10;33(28):3619-33. doi: 10.1038/onc.2013.321. Epub 2013 Aug 12. Review.

13.

Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth.

Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E.

Nat Med. 2011 Oct 30;17(11):1498-503. doi: 10.1038/nm.2492.

14.

The first line of intra-abdominal metastatic attack: breaching the mesothelial cell layer.

Kenny HA, Nieman KM, Mitra AK, Lengyel E.

Cancer Discov. 2011 Jul;1(2):100-2. doi: 10.1158/2159-8290.CD-11-0117.

15.

Targeting the urokinase plasminogen activator receptor inhibits ovarian cancer metastasis.

Kenny HA, Leonhardt P, Ladanyi A, Yamada SD, Montag A, Im HK, Jagadeeswaran S, Shaw DE, Mazar AP, Lengyel E.

Clin Cancer Res. 2011 Feb 1;17(3):459-71. doi: 10.1158/1078-0432.CCR-10-2258. Epub 2010 Dec 13.

16.

{beta}3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer.

Kaur S, Kenny HA, Jagadeeswaran S, Zillhardt MR, Montag AG, Kistner E, Yamada SD, Mitra AK, Lengyel E.

Am J Pathol. 2009 Nov;175(5):2184-96. doi: 10.2353/ajpath.2009.090028. Epub 2009 Oct 1.

17.

Organotypic models of metastasis: A three-dimensional culture mimicking the human peritoneum and omentum for the study of the early steps of ovarian cancer metastasis.

Kenny HA, Dogan S, Zillhardt M, K Mitra A, Yamada SD, Krausz T, Lengyel E.

Cancer Treat Res. 2009;149:335-51. doi: 10.1007/978-0-387-98094-2_16. Review. No abstract available.

18.

MMP-2 functions as an early response protein in ovarian cancer metastasis.

Kenny HA, Lengyel E.

Cell Cycle. 2009 Mar 1;8(5):683-8. Epub 2009 Mar 25.

19.

Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target.

Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel E.

Cancer Res. 2008 Apr 1;68(7):2329-39. doi: 10.1158/0008-5472.CAN-07-5167.

20.

The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin.

Kenny HA, Kaur S, Coussens LM, Lengyel E.

J Clin Invest. 2008 Apr;118(4):1367-79. doi: 10.1172/JCI33775.

Supplemental Content

Loading ...
Support Center